Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma

Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.

Detalles Bibliográficos
Autores principales: Walther, Thomas, Khanna, Prateek, Bhatt, Rupal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489949/
https://www.ncbi.nlm.nih.gov/pubmed/34616864
http://dx.doi.org/10.1080/23723556.2021.1918529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489949/
https://www.ncbi.nlm.nih.gov/pubmed/34616864
http://dx.doi.org/10.1080/23723556.2021.1918529

Ejemplares similares